Cameron Scott — Singularity Hub
Carl June and his colleagues at the University of Pennsylvania have been making waves since they published some successes fighting leukemia with a revolutionary new method. They removed patients’ T cells and genetically modified them to target and kill the cancer. When the T cells were reintroduced into the patients’ bloodstreams, their cancer was often sent into complete remission.
Could similar modifications to the immune system’s fighter pilots provide revolutionary cures for other cancers and even other diseases?
The U. Penn researchers are applying a similar technique to that other hardest-to-treat disease, HIV/AIDS. They recently completed a Phase 1 clinical trial in which they removed HIV-positive patients’ T cells and genetically modified a portion of them to include a rare HIV-resistant genetic mutation of the CCR5 gene (called delta 32).
Comments are closed.